SV2003000600A - Combinacion terapeutica ref. pc11025aado/bb - Google Patents

Combinacion terapeutica ref. pc11025aado/bb

Info

Publication number
SV2003000600A
SV2003000600A SV2001000600A SV2001000600A SV2003000600A SV 2003000600 A SV2003000600 A SV 2003000600A SV 2001000600 A SV2001000600 A SV 2001000600A SV 2001000600 A SV2001000600 A SV 2001000600A SV 2003000600 A SV2003000600 A SV 2003000600A
Authority
SV
El Salvador
Prior art keywords
therapeutic combination
ref
combinations
combination ref
hydroxylic
Prior art date
Application number
SV2001000600A
Other languages
English (en)
Inventor
Shear Charles Lester
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2003000600A publication Critical patent/SV2003000600A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

LA PRESENTE INVENCION SE REFIERE A COMBINACIONES FARMACEUTICAS DE UN INHIBIDOR DE CETP Y ATORVASTATINA O SUS METABOLITOS HIDROXILICOS O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES, METODOS PARA UTILIZAR TALES COMBINACIONES Y KITS QUE CONTIENEN TALES COMBINACIONES PARA EL TRATAMIENTO DE ATEROSCLEROSIS, ANGINA DE PECHO, NIVELES ELEVADOS DE COLESTEROL Y NIVELES BAJOS DE HDL Y PARA EL TRATAMIENTO DEL RIESGO CARDIACO.
SV2001000600A 2000-08-15 2001-08-14 Combinacion terapeutica ref. pc11025aado/bb SV2003000600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22523800P 2000-08-15 2000-08-15

Publications (1)

Publication Number Publication Date
SV2003000600A true SV2003000600A (es) 2003-01-13

Family

ID=22844100

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000600A SV2003000600A (es) 2000-08-15 2001-08-14 Combinacion terapeutica ref. pc11025aado/bb

Country Status (27)

Country Link
US (1) US20020035125A1 (es)
EP (1) EP1309329A2 (es)
JP (1) JP2004506008A (es)
KR (1) KR20030069983A (es)
CN (1) CN1735416A (es)
AP (1) AP2003002743A0 (es)
AU (1) AU2001270937A1 (es)
BG (1) BG107515A (es)
BR (1) BR0113200A (es)
CA (1) CA2419406A1 (es)
CZ (1) CZ2003390A3 (es)
DZ (1) DZ3409A1 (es)
EA (1) EA200300155A1 (es)
EC (1) ECSP034478A (es)
HR (1) HRP20030104A2 (es)
HU (1) HUP0303083A3 (es)
IL (1) IL154348A0 (es)
IS (1) IS6700A (es)
MX (1) MXPA03001419A (es)
NO (1) NO20030725D0 (es)
PA (1) PA8525301A1 (es)
PE (1) PE20020340A1 (es)
SK (1) SK1742003A3 (es)
SV (1) SV2003000600A (es)
TN (1) TNSN01125A1 (es)
UY (1) UY26883A1 (es)
WO (1) WO2002013797A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044459A1 (en) * 2001-09-04 2003-03-06 Pfizer Inc. Biomodulated multiparticulate formulations
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
EP1581210B1 (en) * 2002-12-20 2008-03-19 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
OA13174A (en) * 2003-05-30 2006-12-13 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors.
CN1863511A (zh) * 2003-08-04 2006-11-15 辉瑞产品公司 提供控制释放的胆固醇酯转移蛋白抑制剂以及立即释放的HMG－CoA还原酶抑制剂的剂型
SG146695A1 (en) 2003-09-26 2008-10-30 Japan Tobacco Inc Method of inhibiting remnant lipoprotein production
CN1942428A (zh) * 2004-04-13 2007-04-04 默克公司 Cetp抑制剂
WO2006082500A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
PT2334295T (pt) 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
SI2596786T1 (sl) 2009-02-10 2020-03-31 Amarin Pharmaceuticals Ireland Limited, Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
DK3278665T3 (da) 2009-04-29 2020-11-30 Amarin Pharmaceuticals Ie Ltd Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
NZ611606A (en) 2010-11-29 2015-10-30 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3750536A1 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6462091B1 (en) * 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
TNSN01125A1 (fr) 2005-11-10
AP2003002743A0 (en) 2003-03-31
BG107515A (en) 2003-09-30
PE20020340A1 (es) 2002-05-10
WO2002013797A2 (en) 2002-02-21
NO20030725D0 (no) 2003-02-14
EP1309329A2 (en) 2003-05-14
EA200300155A1 (ru) 2003-08-28
IL154348A0 (en) 2003-09-17
HUP0303083A2 (hu) 2003-12-29
WO2002013797A3 (en) 2003-03-13
DZ3409A1 (fr) 2002-02-21
IS6700A (is) 2003-01-27
BR0113200A (pt) 2003-09-16
UY26883A1 (es) 2002-03-22
CZ2003390A3 (en) 2004-03-17
SK1742003A3 (en) 2004-06-08
HRP20030104A2 (en) 2003-04-30
HUP0303083A3 (en) 2005-05-30
AU2001270937A1 (en) 2002-02-25
MXPA03001419A (es) 2003-06-06
ECSP034478A (es) 2003-03-31
CA2419406A1 (en) 2002-02-21
JP2004506008A (ja) 2004-02-26
US20020035125A1 (en) 2002-03-21
CN1735416A (zh) 2006-02-15
KR20030069983A (ko) 2003-08-27
PA8525301A1 (es) 2002-04-25

Similar Documents

Publication Publication Date Title
SV2003000600A (es) Combinacion terapeutica ref. pc11025aado/bb
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
UY30460A1 (es) Compuestos terapéuticos
HK1082199A1 (en) Transdermal granisetron
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
UY26886A1 (es) Polimorfos de un análogo de epotilona
GT200300053A (es) Compuestos que modulan la actividad de ppar
ECSP088296A (es) Compuestos terapéuticos
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
UY27740A1 (es) Nuevos compuestos
GT200300054A (es) Compuestos que modulan la actividad de ppar
CR8859A (es) Derivados de piridina
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BR112022026186A2 (pt) Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras
BRPI0507859A (pt) uso dos inibidores da colinesterase
WO2003094367A3 (en) Improved first aid kit instructions
PA8555201A1 (es) Formas pseudopolimorficas de carvedilol
HUP0400886A2 (hu) Koleszteril-észter transzfer protein inhibitorok és fibrinsav-származékok kombinációi szív-érrendszeri indikációkhoz
BRPI0508497A (pt) moduladores de canais de ìons e composição que os contém
MXPA02012029A (es) Kit para reducir dolor continuo.
HN2001000119A (es) S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares.
NO20053247D0 (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.
PA8480401A1 (es) Un metodo para la prevencion del inicio del asma
GT200100106A (es) Combinaciones de carboxialquileter - inhibidor de acat.

Legal Events

Date Code Title Description
FD Lapse